Patents Assigned to AbbVie Inc.
  • Patent number: 11312668
    Abstract: The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: April 26, 2022
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Wilfried Braje, Katarina Britze, Justin D. Dietrich, Anais Jolit, Johannes Kaschel, Johanna Klee, Tanja Lindner
  • Patent number: 11285159
    Abstract: The invention described herein relates to methods for treating a human subject with myelofibrosis or an MPN-related disorder, comprising administering navitoclax to the subject optionally in combination with ruxolitinib.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: March 29, 2022
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: John Hayslip, Leanne M. Holes, Sven Mensing, Silpa Nuthalapati
  • Patent number: 11278603
    Abstract: The present invention pertains to an enzyme preparation obtained from e-beam irradiated animal tissue, such as porcine pancreas. The present invention also pertains to methods for making such enzyme preparations, pharmaceutical compositions comprising such enzymes preparations, and methods for using such pharmaceutical compositions and enzyme preparations.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: March 22, 2022
    Assignee: AbbVie Inc.
    Inventors: Martin Babcock, Cynthia Burnell, Vikram Kalthod, Joerg Breitenbach, Frithjof Sczesny, Frauke-Regina Rueffer, George Shlieout
  • Publication number: 20220073559
    Abstract: The present invention relates generally to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide, polymorphic forms thereof, methods for preparation and use thereof, pharmaceutical compositions thereof, and kits and articles of manufacture thereof.
    Type: Application
    Filed: August 6, 2021
    Publication date: March 10, 2022
    Applicant: ABBVIE INC.
    Inventors: Ahmad Y. SHEIKH, Alessandra Mattei, Xiu C. WANG
  • Patent number: 11246866
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: February 15, 2022
    Assignee: AbbVie Inc.
    Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
  • Publication number: 20220017511
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: February 24, 2021
    Publication date: January 20, 2022
    Applicant: AbbVie Inc.
    Inventors: Steven D. Fidanze, Lisa A. Hasvold, Dachun Liu, Keith F. McDaniel, John Pratt, Michael Schrimpf, George Sheppard, Le Wang, Bing Li
  • Publication number: 20220017607
    Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment, and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
    Type: Application
    Filed: February 22, 2021
    Publication date: January 20, 2022
    Applicants: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO KG
    Inventors: Heinz HILLEN, Stefan BARGHORN, Boris LABKOVSKY, Ulrich EBERT, Andreas STRIEBINGER, Patrick KELLER
  • Publication number: 20220008413
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: March 5, 2021
    Publication date: January 13, 2022
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother
  • Patent number: 11198697
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: December 14, 2021
    Assignee: AbbVie Inc.
    Inventors: Ayman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew Mulhern, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder
  • Publication number: 20210380674
    Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an inter leukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
    Type: Application
    Filed: April 27, 2017
    Publication date: December 9, 2021
    Applicant: AbbVie Inc.
    Inventors: Gregg TIMONY, Sheila GUJRATHI, Robert PEACH, Allan OLSON
  • Patent number: 11186584
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: November 30, 2021
    Assignee: AbbVie Inc.
    Inventors: Ayman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew Mulhern, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder
  • Publication number: 20210346369
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: December 1, 2020
    Publication date: November 11, 2021
    Applicant: AbbVie Inc.
    Inventors: Le WANG, George DOHERTY, Xilu WANG, Zhi-Fu TAO, Milan BRUNCKO, Aaron R. KUNZER, Michael D. WENDT, Xiaohong SONG, Robin FREY, Todd M. HANSEN, Gerard M. SULLIVAN, Andrew JUDD, Andrew SOUERS
  • Patent number: 11149043
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: October 19, 2021
    Assignees: Calico Life Sciences LLC, AbbVie Inc.
    Inventors: Michael J. Dart, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, Kathleen Murauski, Marina Pliushchev, Brian S. Brown, Eric Voight, John T. Randolph
  • Publication number: 20210308135
    Abstract: The present invention relates to dosing regimens for GnRH receptor antagonists, and, in particular, dosing regimens for 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1- phenylethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof, in subjects suffering from, for example, endometriosis, adenomyosis, polycystic ovary syndrome (PCOS), or uterine fibroids, to minimize changes in bone mineral density associated with such GnRH receptor antagonists.
    Type: Application
    Filed: August 1, 2019
    Publication date: October 7, 2021
    Applicant: AbbVie Inc.
    Inventor: Mohamad Shebley
  • Publication number: 20210275527
    Abstract: The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for treating such gynecological disorders, where the methods involve administration of elagolix and may further involve co-administration of a CYP2B6 substrate (e.g., bupropion) or a CYP2C19 substrate (e.g., omeprazole).
    Type: Application
    Filed: August 27, 2020
    Publication date: September 9, 2021
    Applicant: AbbVie Inc.
    Inventors: Farah N. Ali, Sheetal P. Dharia, Nael M. Mostafa, Ahmed Nader, Akshanth R. Polepally, Mohamad Shebley
  • Patent number: 11110087
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: September 7, 2021
    Assignees: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • Patent number: 11091507
    Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: August 17, 2021
    Assignee: AbbVie Inc.
    Inventors: Brian P. Enright, Ye Huang, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Peter T. Mayer, Christopher P. Miller, Valentino J. Stella, Eric A. Voight
  • Patent number: D930973
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: September 21, 2021
    Assignee: ABBVIE INC.
    Inventors: Todd Marshall, Bhimaprasad Medhal, John G. Finch, Joy Elizabeth Borgardt
  • Patent number: D930974
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: September 21, 2021
    Assignee: ABBVIE INC.
    Inventors: Todd Marshall, Bhimaprasad Medhal, John G. Finch, Joy Elizabeth Borgardt
  • Patent number: RE48923
    Abstract: The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in one of FIGS. 1-10.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: February 8, 2022
    Assignee: AbbVie Inc.
    Inventors: Jean-Christophe Califano, Michael G. Fickes, Lars Fredrik Nordstroem